Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis), but they eventually acquire resistance. Preclinical studies yielded several PARPi resi...

Full description

Saved in:

Bibliographic Details
Published in:	Cell reports (Cambridge) Vol. 42; no. 5; p. 112538
Main Authors:	Bhin, Jinhyuk, Paes Dias, Mariana, Gogola, Ewa, Rolfs, Frank, Piersma, Sander R., de Bruijn, Roebi, de Ruiter, Julian R., van den Broek, Bram, Duarte, Alexandra A., Sol, Wendy, van der Heijden, Ingrid, Andronikou, Christina, Kaiponen, Taina S., Bakker, Lara, Lieftink, Cor, Morris, Ben, Beijersbergen, Roderick L., van de Ven, Marieke, Jimenez, Connie R., Wessels, Lodewyk F.A., Rottenberg, Sven, Jonkers, Jos
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 30.05.2023 Cell Press Elsevier
Subjects:	BRCA1 BRCA2 breast cancer CP: Cancer homologous recombination multi-omics PARP inhibitor therapy resistance homologous recombination CP: Cancer PARP inhibitor multi-omics breast cancer BRCA1 BRCA2 therapy resistance
ISSN:	2211-1247, 2211-1247
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!